LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

103.29 -2.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

99.21

Max

103.59

Chiffres clés

By Trading Economics

Revenu

7.2M

-93M

Ventes

33M

265M

Marge bénéficiaire

-34.965

Employés

1,999

EBITDA

6.6M

-82M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+28.24% upside

Dividendes

By Dow Jones

Prochains Résultats

29 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

4.6B

14B

Ouverture précédente

105.66

Clôture précédente

103.29

Sentiment de l'Actualité

By Acuity

50%

50%

141 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 févr. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 févr. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 févr. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 févr. 2026, 23:21 UTC

Résultats

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 févr. 2026, 23:20 UTC

Résultats

Nickel Industries 2025 Operating Profit US$126.4 Million

22 févr. 2026, 23:19 UTC

Résultats

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 févr. 2026, 23:19 UTC

Résultats

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 févr. 2026, 23:18 UTC

Résultats

Nickel Industries Won't Pay a Final Dividend

22 févr. 2026, 23:16 UTC

Résultats

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 févr. 2026, 21:35 UTC

Résultats

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 févr. 2026, 21:34 UTC

Résultats

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 févr. 2026, 21:34 UTC

Résultats

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 févr. 2026, 21:33 UTC

Résultats

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 févr. 2026, 21:33 UTC

Résultats

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 févr. 2026, 21:28 UTC

Résultats

Ampol Final Dividend A$0.60/Share

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Revenue A$31.37 Billion, Down 10%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 févr. 2026, 14:31 UTC

Acquisitions, Fusions, Rachats

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 févr. 2026, 23:12 UTC

Acquisitions, Fusions, Rachats

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 févr. 2026, 22:12 UTC

Résultats

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 févr. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 févr. 2026, 21:23 UTC

Résultats

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 févr. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 févr. 2026, 21:01 UTC

Acquisitions, Fusions, Rachats

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 févr. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

28.24% hausse

Prévisions sur 12 Mois

Moyen 132.22 USD  28.24%

Haut 175 USD

Bas 110 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

19

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

141 / 351Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat